Ascendis Pharma initiates TransCon Treprostinil Phase 1 study in healthy volunteers Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical requirements, today announced that it has initiated a Phase 1 single ascending dosage research of TransCon Treprostinil in healthy volunteers. TransCon Treprostinil is being developed to take care of pulmonary arterial hypertension, a life-threatening orphan disease characterized by elevated blood circulation pressure in the pulmonary arteries. TransCon Treprostinil provides been designed as an inert prodrug that allows a sustained launch of unmodified treprostinil in circulation carrying out a once-daily self-administered subcutaneous injection single dose .
Drug firm participation increased from 44 % in 1993 to 58 % in 2003. Most importantly, they recognized statistically significant distinctions between research supported by pharmaceutical research and the ones that did not. Research with pharmaceutical participation or support were more likely to report excellent results, favoring the experimental therapy. These studies also were a lot more likely to use single arm designs – that is, a scholarly study whose patients get the same treatment with no control group to review efficacy. Drug company sponsored trials have a tendency to target sufferers with advanced disease also. While these types of studies are important for identifying brand-new effective drugs, they could not answer questions about optimal dosing, period and identification of individuals who may have better or worse outcomes on treatment – essential clinical elements for treatment recommendations.